Tag: Cancer: Breast
Sacituzumab Govitecan Promising in Triple-Negative Breast Cancer
Response rate of 33.3 percent, median response duration of 7.7 months observed in 108 patients
Oncotype DX Not Cost-Effective for Low-Risk Breast Cancer
Incremental cost-effectiveness ratio varies across clinical risk groups, sensitive to patient age
USPSTF Says Screen Women With Higher Risk for BRCA Mutations
Those with positive results should be provided with genetic counseling, testing if indicated
p, p’-DDT Exposure Linked to Breast Cancer Through Age 54
Risk for breast cancer varies based on timing of first exposure, age at diagnosis
More Than a Half Million Deaths From Breast Cancer Averted
Percent of breast cancer mortality reductions varied from 45.3 to 58.3 percent from 1989 to 2018
Outcomes Good for Autologous Reconstruction After Implant Fail
Autologous breast reconstruction associated with improved patient satisfaction, quality of life
Use of Image Analysis to ID HER2 Status in Breast Cancer Outlined
Guideline addresses use of quantitative image analysis to interpret HER2 immunohistochemistry
Long-Term Incidence of A-Fib Increased in Women With Breast Cancer
Women younger than 60 years have increased short-term, longer-term risk
Time to Breast Cancer Surgery Delayed for Non-Hispanic Blacks
Racial differences in TTS did not explain racial differences in overall survival with breast-conserving sx
Breast Cancer Patients Do Not Overreact to Genetic Testing
No increased cancer worry for multigene panel testing versus BRCA1/2-only test after cancer diagnosis
